In this study, we employed a previously developed peptide–oligonucleotide conjugate, combining a PD-L1-binding peptide with anti-miR-21 (P21), as a therapeutic approach for tumor-targeted delivery of anti-miR-21 in a DOX-resistant 4T1 TNBC model [30]. The gene discussed is CD274; the disease is neoplasm.